JO3156B1 - ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا - Google Patents

ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا

Info

Publication number
JO3156B1
JO3156B1 JOP/2010/0245A JOP20100245A JO3156B1 JO 3156 B1 JO3156 B1 JO 3156B1 JO P20100245 A JOP20100245 A JO P20100245A JO 3156 B1 JO3156 B1 JO 3156B1
Authority
JO
Jordan
Prior art keywords
malaria
compositions
treatment
parasitic diseases
fused imidazoles
Prior art date
Application number
JOP/2010/0245A
Other languages
English (en)
Inventor
K Chatterjee Arnab
S Nagle Advait
Wu Tao
C Tully David
L Kuhen Kelli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3156(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3156B1 publication Critical patent/JO3156B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

الإختراع يوفر نوع من المركبات، تراكيب صيدلانية تشمل مثل هذه المركبات وطرق إستعمال مثل هذه المركبات لمعالجة أو منع الملاريا.
JOP/2010/0245A 2009-07-09 2010-07-08 ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا JO3156B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22443309P 2009-07-09 2009-07-09

Publications (1)

Publication Number Publication Date
JO3156B1 true JO3156B1 (ar) 2017-09-20

Family

ID=42727573

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0245A JO3156B1 (ar) 2009-07-09 2010-07-08 ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا

Country Status (37)

Country Link
US (3) US8557801B2 (ar)
EP (2) EP2451814B1 (ar)
JP (1) JP5432376B2 (ar)
KR (1) KR101378666B1 (ar)
CN (1) CN102471341B (ar)
AR (1) AR077463A1 (ar)
AU (1) AU2010271247B2 (ar)
BR (1) BR112012000413B1 (ar)
CA (1) CA2767664C (ar)
CL (1) CL2012000042A1 (ar)
CO (1) CO6491060A2 (ar)
CR (1) CR20120008A (ar)
CU (1) CU24155B1 (ar)
DK (1) DK2451814T3 (ar)
EA (1) EA019655B1 (ar)
EC (1) ECSP12011585A (ar)
ES (2) ES2477940T3 (ar)
GT (1) GT201200004A (ar)
HN (1) HN2012000023A (ar)
HR (1) HRP20140641T1 (ar)
IL (1) IL217384A (ar)
JO (1) JO3156B1 (ar)
MA (1) MA33419B1 (ar)
MX (1) MX2012000389A (ar)
MY (1) MY157238A (ar)
NZ (1) NZ597275A (ar)
PE (1) PE20130399A1 (ar)
PL (1) PL2451814T3 (ar)
PT (1) PT2451814E (ar)
SG (1) SG176938A1 (ar)
SI (1) SI2451814T1 (ar)
SM (1) SMT201400096B (ar)
TN (1) TN2011000647A1 (ar)
TW (1) TWI421252B (ar)
UA (1) UA103930C2 (ar)
UY (1) UY32776A (ar)
WO (1) WO2011006143A2 (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209461A (zh) * 2012-11-14 2015-12-30 霍夫曼-拉罗奇有限公司 咪唑并吡啶衍生物
LT2925757T (lt) * 2012-11-19 2017-12-27 Novartis Ag Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
JP2016500073A (ja) * 2012-11-19 2016-01-07 ノバルティス アーゲー 寄生虫病の処置のための化合物および組成物
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
CN103126782B (zh) * 2013-02-26 2016-06-29 内蒙古农牧业科学院 一种寄生病的治疗方法
JP6392352B2 (ja) * 2013-12-19 2018-09-19 ノバルティス アーゲー リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
CA2994027C (en) 2015-07-31 2023-10-10 Merck Patent Gmbh Bicyclic heterocyclic derivatives
AU2017314083B2 (en) * 2016-08-15 2020-12-10 Bayer Aktiengesellschaft Condensed bicyclic heterocycle derivatives as pest control agents
CN110691597A (zh) 2017-04-24 2020-01-14 诺华股份有限公司 2-氨基-1-(2-(4-氟苯基)-3-(4-氟苯基氨基)-8,8-二甲基-5,6-二氢咪唑并[1,2-a]吡嗪-7(8H)-基)乙酮及其组合的治疗方案
CN119613408A (zh) 2017-07-14 2025-03-14 豪夫迈·罗氏有限公司 二环酮化合物及其使用方法
CA3075813A1 (en) * 2017-10-04 2019-04-11 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor sall4 and uses thereof
TWI820231B (zh) * 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
WO2022049548A1 (en) 2020-09-04 2022-03-10 Novartis Ag Kaf156 combinations and methods for the treatment of malaria
WO2023168107A2 (en) * 2022-03-04 2023-09-07 University Of Central Florida Research Foundation, Inc. Compounds and compositions for anitmalarial therapeutic and prophylactic use
CN114569711B (zh) * 2022-03-24 2024-04-19 安徽医科大学 一种预防弓形虫病的ME49Δcdpk3减毒活疫苗及其制备方法和应用
WO2024006970A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
WO2024006971A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
US20250388603A1 (en) * 2022-07-01 2025-12-25 The Scripps Research Institute Antimalarial compounds
WO2026018203A1 (en) * 2024-07-19 2026-01-22 Novartis Ag Aminoisoquinoline compounds and methods of using thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK476885D0 (da) 1985-10-17 1985-10-17 Ferrosan As Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
HUP0202648A3 (en) 1998-06-12 2003-02-28 Sod Conseils Rech Applic Imidazolyl derivatives, pharmaceutical compositions containing them and their use
FR2780974B1 (fr) 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
ES2328564T3 (es) * 1998-12-31 2009-11-16 Ipsen Pharma Inhibidores de la prenil transferasa.
PT1233787E (pt) 1999-11-09 2005-04-29 Conseils Rech S Et D Applic Sc Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
FR2803525B1 (fr) 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
US7566734B2 (en) 2000-08-01 2009-07-28 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
CA2432578C (en) * 2001-01-02 2008-04-01 F. Hoffmann-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
FR2825278A1 (fr) 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
EP1490335B1 (en) 2002-03-25 2007-09-19 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1542691B1 (en) 2002-09-27 2009-01-07 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Composition for the treatment of nasopharyngeal carcinoma and use thereof
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
EP1583534A4 (en) * 2002-12-20 2007-08-29 Merck & Co Inc 3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
EP1603900A4 (en) * 2003-03-06 2008-08-20 Merck & Co Inc IMIDAZOPYRIDIN COMPOUNDS WITH EFFECT AGAINST PROTOZOEN
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004103276A2 (en) 2003-05-14 2004-12-02 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2867778B1 (fr) * 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
WO2007017423A2 (en) 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
CA2650007A1 (en) 2006-04-21 2007-11-01 Smithkline Beecham Corporation Il-8 receptor antagonists
WO2008006085A2 (en) 2006-07-07 2008-01-10 University Of Washington Compositions and methods for predicting inhibitors of protein targets
TW200808056A (en) * 2006-07-26 2008-02-01 Compal Communications Inc Rear projection display system
CA2676138A1 (en) * 2007-01-26 2008-08-07 Irm Llc Compounds and compositions as kinase inhibitors
US20080242862A1 (en) * 2007-03-27 2008-10-02 Calderwood David J Novel imidazo based heterocycles
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
CN101357922B (zh) 2007-08-02 2011-05-18 山东轩竹医药科技有限公司 新的dpp-iv抑制剂
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2300466B1 (en) 2008-06-20 2014-08-06 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
PE20130399A1 (es) 2013-04-06
MY157238A (en) 2016-05-13
US20110059934A1 (en) 2011-03-10
SI2451814T1 (sl) 2014-08-29
CN102471341B (zh) 2014-07-02
ES2574529T3 (es) 2016-06-20
US8557801B2 (en) 2013-10-15
PT2451814E (pt) 2014-07-16
KR20120047939A (ko) 2012-05-14
EA201200098A1 (ru) 2012-07-30
US9963454B2 (en) 2018-05-08
SMT201400096B (it) 2014-09-08
US9469645B2 (en) 2016-10-18
EA019655B1 (ru) 2014-05-30
CR20120008A (es) 2012-03-12
HK1164304A1 (en) 2012-09-21
CA2767664C (en) 2013-12-10
JP5432376B2 (ja) 2014-03-05
EP2737927A1 (en) 2014-06-04
MA33419B1 (ar) 2012-07-03
JP2012532890A (ja) 2012-12-20
GT201200004A (es) 2014-03-27
CL2012000042A1 (es) 2012-12-21
AR077463A1 (es) 2011-08-31
EP2737927B1 (en) 2016-03-30
UY32776A (es) 2011-02-28
TW201105675A (en) 2011-02-16
US20130281403A1 (en) 2013-10-24
CU20120002A7 (es) 2012-06-21
CN102471341A (zh) 2012-05-23
DK2451814T3 (da) 2014-07-14
IL217384A0 (en) 2012-02-29
TWI421252B (zh) 2014-01-01
KR101378666B1 (ko) 2014-03-26
WO2011006143A2 (en) 2011-01-13
CU24155B1 (es) 2016-03-31
US20160108051A1 (en) 2016-04-21
HRP20140641T1 (hr) 2014-09-26
AU2010271247A1 (en) 2012-01-19
NZ597275A (en) 2013-05-31
WO2011006143A3 (en) 2011-06-09
EP2451814B1 (en) 2014-04-09
EP2451814A2 (en) 2012-05-16
SG176938A1 (en) 2012-01-30
HN2012000023A (es) 2014-08-18
CA2767664A1 (en) 2011-01-13
BR112012000413B1 (pt) 2022-02-15
PL2451814T3 (pl) 2014-09-30
ES2477940T3 (es) 2014-07-18
ECSP12011585A (es) 2012-02-29
BR112012000413A2 (pt) 2020-08-11
AU2010271247B2 (en) 2013-07-18
CO6491060A2 (es) 2012-07-31
TN2011000647A1 (en) 2013-05-24
UA103930C2 (ru) 2013-12-10
IL217384A (en) 2015-07-30
MX2012000389A (es) 2012-03-07

Similar Documents

Publication Publication Date Title
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
IN2012DN00971A (ar)
IN2012DN03883A (ar)
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
CA2871471C (en) Dna-pk inhibitors
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
IN2012DN02471A (ar)
MX2012004780A (es) Inhibidores de akt.
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
PH12014502032A1 (en) Treatment of brain cancer
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
MX367327B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
PH12014502065A1 (en) Vesicular formulations
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
UA44410U (en) Method for treatment of hepaticocholedoch strictures
CY1115356T1 (el) Συντηγμeνες ιμιδαζολες και συνθεσεις περιλαμβανοντας αυτες για την αγωγη παρασιτικων παθησεων, οπως ειναι π.χ. η ελονοσια
TN2010000463A1 (en) Compositions and methods for preparing and using same
TH149179A (th) องค์ประกอบทางเภสัชกรรม, รูปแบบเภสัชภัณฑ์, กระบวนการในการเตรียมองค์ประกอบ และรูปแบบดังกล่าว, วิธีการในการรักษา และการใช้องค์ประกอบและรูปแบบดังกล่าว
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази